Editorial: BRCA1 and BRCA2 genes mutations screening in sporadic breast cancer patients in Kazakhstan
Main Article Content
Article Details
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Revised 7/16/2018. Revision Description: Removed outdated link.
References
Lynch, H.T., et al., Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat, 1990. 15(2): p. 63-71.
Pharoah, P.D., et al., Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer, 1997. 71(5): p. 800-9.
Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2012, 2012.
Foulkes, W.D., Inherited susceptibility to common cancers. N Engl J Med, 2008. 359(20): p. 2143-53.
Pharoah, P.D., et al., Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet, 2002. 31(1): p. 33-6.
Miki, Y., et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994. 266(5182): p. 66-71.
Wooster, R., et al., Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 1994. 265(5181): p. 2088-90.
Woodward, A.M., et al., Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet, 2005. 42(5): p. e31.
Shannon, K.M. and A. Chittenden, Genetic testing by cancer site: breast. Cancer J. 18(4): p. 310-9.
Levy-Lahad, E., et al., Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet, 1997. 60(5): p. 1059-67.
King, M.C., J.H. Marks, and J.B. Mandell, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 2003. 302(5645): p. 643-6.
Brookes, A.J., The essence of SNPs. Gene, 1999. 234(2): p. 177-86.
Collins, K.J., Physiological variation and adaptability in human populations. Ann Hum Biol, 1999. 26(1): p. 19-38.
Bentley, D.R., The Human Genome Project--an overview. Med Res Rev, 2000. 20(3): p. 189-96.
Lindor, N.M., et al., A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat, 2012. 33(1): p. 8-21.
Chenevix-Trench, G., et al., Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res, 2006. 66(4): p. 2019-27.
Easton, D.F., et al., A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet, 2007. 81(5): p. 873-83.
Goldgar, D.E., et al., Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet, 2004. 75(4): p. 535-44.
Gomez Garcia, E.B., et al., A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res, 2009. 11(1): p. R8.
Spurdle, A.B., et al., Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators. J Clin Oncol, 2008. 26(10): p. 1657-63.
Whiley, P.J., et al., Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat. 32(6): p. 678-87.
Tavtigian, S.V., et al., Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat, 2008. 29(11): p. 1342-54.
Spurdle, A.B., et al., ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 33(1): p. 2-7.
Thorisson, G.A. and L.D. Stein, The SNP Consortium website: past, present and future. Nucleic Acids Res, 2003. 31(1): p. 124-7.
Iversen, E.S., Jr., et al., A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. Cancer Epidemiol Biomarkers Prev. 20(6): p. 1078-88.
Millot, G.A., et al., A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat.
Plon, S.E., et al., Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat, 2008. 29(11): p. 1282-91.
Lindor, N.M., et al., A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat. 33(1): p. 8-21.